Also in this section

• News Home
• News Archive
• Low back pain trial now recruiting in Sydney
• Leading Institute stroke specialist wins prestigious RPA Research Medal
• Communications, partnerships critical in improving Indigenous health
• Presentations from Cardiovascular and Metabolic Medicine meeting 2008 now available
• Weight watching in China
• Scaling-up HIV interventions in India
• Preventing depression after stroke
• Cracking the problem of whiplash
• ADVANCE trial shows combined treatments provide 33% reduction of serious kidney complications in type 2 diabetes
• 'China too must confront obesity' according to Institute researchers
• The George Institute, China now able to host Fogarty International Clinical Research Fellows
• United Arab Emirates and Australia join forces in health and safety research
• Salt warning on sausage sizzles!
• Low back pain recovery slow: and worse for those on compensation
• Fiona Turnbull awarded the International Society of Hypertension AstraZeneca award
• Staff Profile - Dr Bassel Hassan
• Daily burden of epilepsy can outweigh clinical symptoms
• John Chalmers honoured with Alberto Zanchetti Life Achievement Award
• The largest ever study of diabetes shows intensive glucose control reduces serious complications
• David Jayne, Diabetes Patient & ADVANCE study participant
• Falls prevention research shows innovation is required
• Achieving global equity in treating kidney disease
• Staff Profile-Dr Vibeke Anna
• Fulbright Indigenous Scholarship: supporting young Indigenous leaders
• New musculoskeletal focus at The George
• Landmark study shows combination therapy of no benefit to heart patients and should be avoided
• Depression, disability keep around half of stroke survivors from working
• Australian research institute receives $8.8m grant from Bill & Melinda Gates Foundation
• Does protective clothing help prevent injury in a motorcycle crash?
• A ten percent lowering of 'bad' LDL-cholesterol could save 3,000 Australian lives a year

INIT II - Type 1 diabetes nasal spray vaccine trial now recruiting

Participants are currently being recruited for the clinical trial of an intranasal insulin spray that is being tested to determine whether it provides protection against the onset of type 1 diabetes. This trial is being run by the Diabetes Vaccine Development Centre.

Type 1 diabetes (formerly known as juvenile diabetes) is usually diagnosed in children before the age of 15 years, though it can occur later in life. It is one of the most costly and chronic childhood diseases and treatment involves taking multiple insulin injections and blood sugar level tests every day.

There is significant evidence suggesting that the administration of intranasal insulin can induce protective immunity thus preventing or postponing the onset of type 1 diabetes. This approach has shown promise in both preclinical and early stage clinical testing.

People are eligible to enter the screening phase of the trial if they have a close* relative with type 1 diabetes, are aged between 4 and 30 and are otherwise healthy. Participants at this phase, will be asked to have a blood test to ascertain if they are eligible to go on to the next stage of the trial. Only a small proportion of people who register will be eligible for the further testing required before they can enter the clinical trial phase.

The George Institute will be conducting web development and supporting data management, statistics, and monitoring of the study on behalf of the DVDC.

For more information on the trial, visit www.stopdiabetes.com.au.

*the relative needs to be first or second-degree - this includes parents, children, siblings, half-siblings, aunts, uncles and grandparents.